Get the Stockscreener App
12.24
4.23%
-0.54
Neuropace Inc stock is traded at $12.24, with a volume of 156.05K.
It is down -4.23% in the last 24 hours and down -13.19% over the past month.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
See More
Previous Close:
$12.78
Open:
$12.85
24h Volume:
156.05K
Relative Volume:
1.50
Market Cap:
$420.13M
Revenue:
$99.53M
Net Income/Loss:
$-21.57M
P/E Ratio:
-18.87
EPS:
-0.6488
Net Cash Flow:
$-9.84M
1W Performance:
-3.39%
1M Performance:
-13.19%
6M Performance:
-20.93%
1Y Performance:
+15.04%
1-Day Range:
$12.13
$12.85
1-Week Range:
$12.13
$13.27
52-Week Range:
$9.22
$19.60
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
12.24 | 420.13M | 99.53M | -21.57M | -9.84M | -0.6488 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-26 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-23-26 | Initiated | Mizuho | Outperform |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
After shares were withheld for taxes, NeuroPace (NPCE) medical chief Martha Morrell held 51,357 shares. - Stock Titan
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Form 4 Neuropace Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Neuropace Inc For: 22 September By Investing.com - Investing.com Nigeria
Form 4 Neuropace Inc For: 22 September - Investing.com India
NeuroPace CFO Patrick Williams Discloses Tax-Related Share Withholding on RSU Vesting - kalkinemedia.com
NeuroPace (NPCE) CFO has 1,162 shares withheld for taxes - Stock Titan
Precision Trading with Neuropace Inc. (NPCE) Risk Zones - Stock Traders Daily
Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCE - MarketBeat
First Light Asset Management, LLC Adds 1.34 Million NeuroPace In - GuruFocus
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report? - Yahoo Finance
First Light Asset Management LLC Boosts Stake in NeuroPace, Inc. $NPCE - MarketBeat
NeuroPace Inc. (NPCE) Eases 1.76% to $14.50 as Shares Sit Mid-Range Between Support and ResistanceVolume Gap - siam.in
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com India
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com Canada
NeuroPace at Cantor healthcare conference: growth, data and FDA path By Investing.com - Investing.com UK
NeuroPace at Wells Fargo conference: IGE push faces FDA test By Investing.com - Investing.com Canada
NeuroPace at Wells Fargo conference: IGE push faces FDA test By Investing.com - Investing.com India
NPCE: Strong clinical data and regulatory progress position the RNS system for significant growth in epilepsy care - tradingview.com
NeuroPace at Wells Fargo conference: IGE push faces FDA test - Investing.com
NeuroPace (NPCE) CEO uses 1,310 shares to cover taxes - Stock Titan
Over 12% of NeuroPace (NPCE) may be owned by one investor - Stock Titan
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now - Yahoo Finance
Man Group plc Makes New $1.34 Million Investment in NeuroPace, Inc. $NPCE - MarketBeat
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc. - MarketBeat
Precision Trading with Neuropace Inc. (NPCE) Risk Zones - Stock Traders Daily
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - marketscreener.com
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - Business Wire
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference - Business Wire
Wells Fargo conference to feature NeuroPace fireside chat Sept. 8 - Stock Titan
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace (NPCE) CEO settles RSU tax bill with 1,126 shares - Stock Titan
NeuroPace (NASDAQ: NPCE) CMO has 358 shares withheld for taxes - Stock Titan
NeuroPace Inc (NPCE) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Neuropace (NPCE) Results Check: EPS Lands Above Forecast; Share Move: Shares Finish 1.22% Up on the DayGeographic Revenue Trends - dars.gov.et
Deutsche Bank AG Acquires Shares of 938,919 NeuroPace, Inc. $NPCE - MarketBeat
Neuropace (NPCE) Stock: Ends Up by 0.07% at $14.03; Technical Setup: the $13.33 to $14.73 Range Remains in Focus at the CloseMFI Oversold - vinanet.vn
Neuropace (NPCE) Stock: Ends Up by 0.07% at $14.03; Technical Setup: the $13.33 to $14.73 Range Remains in Focus at the CloseNHNL Ratio - dars.gov.et
Neuropace (NPCE) Market: Posts a 0.07% Gain to $14.03 in the Current Update; Technical View: the $13.33 to $14.73 Range Remains in Focus in Latest TradingPassive Flow - vinanet.vn
HC Wainwright Has Positive Outlook of NeuroPace Q3 Earnings - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for NeuroPace - MarketBeat
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayTrend Following Picks - vinanet.vn
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayWave Equality - dars.gov.et
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayQuality ETF - dars.gov.et
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Yahoo Finance
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? - Yahoo Finance
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - Yahoo Finance
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neuropace Inc Stock (NPCE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MARTHA J MORRELL | Officer |
Dec 15 '25 |
Proposed Sale |
16.19 |
25,000 |
404,750 |
0 |
5.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):